Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659212 | 0.84 | MAP2K1 (0.43) | MAPTHTTNPSR1KDM4ESYK | |
| SCHEMBL1111265 | 0.84 | MAP2K1 (0.58) | MAP2K1 | |
| SCHEMBL14087521 | 0.83 | HSD17B10 (0.52) | ALDH1A1MAPTHTTNPSR1KDM4E | |
| SCHEMBL1111213 | 0.81 | MAP2K1 (0.44) | ALDH1A1MAPTHTTNPSR1KDM4E | |
| SCHEMBL1111126 | 0.79 | EPAS1 (0.37) | MAP2K1BRAFKDR | |
| SCHEMBL1111176 | 0.74 | MAP2K1 (0.53) | HTTHPGDMAP2K1 | |
| SCHEMBL29730783 | 0.74 | RAB9A (0.48) | ALDH1A1MAPTHTTKDM4EHPGD | |
| SCHEMBL12709523 | 0.73 | MAP2K1 (0.64) | MAP2K1 | |
| SCHEMBL14087520 | 0.73 | HPGD (0.47) | ALDH1A1MAPTHTTNPSR1KDM4E | |
| SCHEMBL5474962 | 0.73 | MEN1 (0.56) | ALDH1A1MAPTNPSR1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993630-B2 | Substituted sulphonamido phenoxybenzamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-20110237592-A1 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110218219-A1 | SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2279166-A1 | SUBSTITUTED PHENOXYBENZAMIDES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-02 | — | — | EP | disclosed |
| WO-2010051933-A2 | SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
| EP-2155659-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009129938-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2009-03-26 | — | — | US | disclosed |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2009-03-26 | — | — | US | disclosed |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2009-03-26 | — | — | US | disclosed |
| WO-2008138639-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237592-A1 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES | EDNRB, CCNB3, FLT1 | ALDH1A1 3401/4885MAPT 3700/4885HTT 2364/4885 |
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | MKI67, CDK4, VHL | ALDH1A1 2315/4885MAPT 2531/4885HTT 1402/4885 |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | CCNB3, VEGFA, CCND2 | ALDH1A1 1879/4885MAPT 3090/4885HTT 1159/4885 |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | MKI67, CDK4, VHL | ALDH1A1 2315/4885MAPT 2531/4885HTT 1402/4885 |
| US-20110218219-A1 | SUBSTITUTED SULPHONAMIDO PHENOXYBENZAMIDES | CCNB3, MKI67, RB1 | ALDH1A1 2049/4885MAPT 4052/4885HTT 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.